Currently Viewing:
Newsroom
Currently Reading
Switchable CAR T Cells May Be Safer in Pancreatic Cancer
October 19, 2018 – David Bai, PharmD
Combination of Bleomycin and G-CSF Does Not Increase Risk for Bleomycin-Induced Pulmonary Toxicity
October 17, 2018 – Jaime Rosenberg
Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial
October 17, 2018 – Samantha DiGrande
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14, 2018 – Laura Joszt
ACOs Had No Significant Impact on Spending for Patients With Cancer
October 14, 2018 – Laura Joszt
Know the Risk: 5 Breast Cancer Risk Factors
October 12, 2018 – Samantha DiGrande
The US Oncology Network Announces Highly Positive MIPS Results for 2017
October 12, 2018 – Laura Joszt
Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds
October 11, 2018 – Laura Joszt
NCCN Releases Patient Guidelines for Neuroendocrine Tumors
October 10, 2018 – Samantha DiGrande

Switchable CAR T Cells May Be Safer in Pancreatic Cancer

David Bai, PharmD
Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.
Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.

PDAC is the fourth leading cause of cancer-related deaths, with less than 20% of patients having resectable tumors. While CAR T-cell treatments have shown substantial efficacy in hematological malignancies, outcomes in solid tumors such as pancreatic cancer have been limited. Further, since the antigen is expressed on tumors as well as normal tissue, CAR T-cell toxicities can affect healthy organs as well. Attempts are currently being made to create “switchable” CAR T cells whose activity can be titrated in vivo so that they are more specific toward tumors. Allowing CAR T cells to bind a peptide specifically onto a tumor-binding Fab molecule creates a bridge that can connect the target tumor and effector T-cells, thereby regulating treatment and enhancing safety. 

In their study published in Gut, Raj et al used CAR T cells drawn from patients with stage IV PDAC to determine if switchable CAR T cells have comparable efficacy as conventional CAR-T cells while targeting HER2, a viable target in PDAC. When comparing conventional CAR-T cells with switchable CAR-T cells, both were able to induce cytotoxicity in HER2-expressing PDAC cells. In addition, when an inactive switch of a wild-type HER2 Fab was placed, there was no cytotoxic effect on PDAC cells, identifying the importance of the switch. 

To further examine the effectiveness of CAR T cells in PDAC, investigators created a microenvironment of cancer stem cells—a physical barrier for T cell connection with tumor cells in vitro. Following a few days of culture, CAR T-cell activity was observed in both treatment groups, marked by increased T cell proliferation and enhanced production of the cytotoxic molecule granzyme B. 

Subsequent studies evaluated the efficacy of HER2 CAR T and switchable CAR T cells in vivo. Immunocompromised mice were implanted with patient PDAC cells and treated with both types of CAR T-cell therapy. Non-invasive bioluminescence imaging of the mice showed reduced tumor growth by day 3 and tumors disappeared by day 10 as. However, mice that had received no treatment or CAR T-cell treatment with an inactive switch continued to progress. 

The efficacy of switchable CAR T and conventional CAR T therapy were also compared through dose titrations. Similar tumor regression was observed in both treatment groups, with similar interferon and tumor necrosis factor cytokine release at each T cell dose, with the exception that IL-2 was higher in the conventional CAR-T cell group. 

Finally, when comparing conventional CAR T with switchable CAR T-cell therapy in disseminated metastasis, rapid tumor clearance was observed in both treatment groups. The mice treated with either therapies remained tumor free for the remainder of the study, which was 5 months following T cell administration. From these mouse models, it seems that switchable CAR T therapy can be effectively used to treat PDAC even in the more advanced cases, while also having a better safety profile than conventional CAR-T therapy.

Reference

Raj D, Yang M, Rodgers D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma [published online August 18, 2018]. Gut.doi: 10.1136/gutjnl-2018-316595.

Related Articles

Rucaparib May Have Potential Clinical Benefit for Advanced Pancreatic Cancer
Single Resistant Cell Causes Case of Rare ALL Relapse After CAR T Therapy
Researcher Looks Ahead to Future Improvements in CAR T
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up